Oncology

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Expert Perspectives in Relapsed/Refractory Diffuse Large B-Cell Lymphoma to Cover Key Topics in R/R DLBCL Treatment

expert perspectives by Brad Kahl, MD; Jeremy S. Abramson, MD, MMSc; Matthew J. Matasar, MD

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Relapsed/Refractory Diffuse Large B-Cell Lymphoma will feature selected topics in R/R DLBCL that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts:

Jeremy S. Abramson, MD, MMSc

Director, Jon and JoAnn Hagler Center for Lymphoma
Jon and JoAnn Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Brad Kahl, MD

Professor of Medicine, Division of Oncology
Washington University School of Medicine
Director, Lymphoma Program
Alvin J. Siteman Cancer Center
Saint Louis, MO

Matthew J. Matasar, MD

Associate Member, Lymphoma Service
Section Head, Aggressive B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
New York, NY

Community-Selected Topics:

Expert Roundtables

•   Therapeutic Sequencing in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
•   Investigational and Emerging Therapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
•   Improving Outcomes for Patients With High-Risk Diffuse Large B-Cell Lymphoma
•   Curative Intent in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Different Paths and Different Strategies

Clinical Topic Updates

•   Predictive Biomarkers for Chimeric Antigen Receptor T-Cell Therapy
•   Novel Agents as Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
•   Double Hit, Triple Hit, and Cell of Origin in Diffuse Large B-Cell Lymphoma
•   CD19-Directed Therapies and Antibody-Drug Conjugates for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patient Care Perspectives

•   "Off-the-Shelf" Treatment Options in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
•   Safety and Tolerability of Salvage Therapy and Later-Line Treatments in Diffuse Large B-Cell Lymphoma
•   Options for Patients Who Do Not Proceed to Autologous Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy
•   Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Assessing the Patient’s Treatment Goals

Profile

Brad Kahl, MD

Professor of Medicine, Division of Oncology
Washington University School of Medicine
Director, Lymphoma Program
Alvin J. Siteman Cancer Center
Saint Louis, MO